An oxadiazole-based compound potentiates anti- tuberculosis treatment by increasing host resistance via zinc poisoning
Maure, A.; Lawaree, E.; Fiorentino, F.; Pawlik, A.; Gona, S.; Giraud-Gatineau, A.; Eldridge, M. J. G.; Danckaert, A.; Hardy, D.; Frigui, W.; Keck, C.; Aulner, N.; Mai, A.; Hamon, M.; Barreiro, L. B.; Brodin, P.; Brosch, R.; Rotili, D.; Tailleux, L.
Show abstract
Anti-tuberculosis drugs, mostly developed over 60 years ago, combined with a poorly effective vaccine, have failed to eradicate tuberculosis. More worryingly, multi-resistant strains of Mycobacterium tuberculosis are constantly emerging. Innovative strategies are thus urgently needed to improve tuberculosis treatment. Recently, host-directed therapy has emerged as a promising strategy to be used in adjunct with existing or future antibiotics, by improving innate immunity or limiting immunopathology. Here, using high content imaging, we identified novel 1,2,4-oxadiazole-based compounds, that allow human macrophages to control MTB replication. Genome-wide gene expression analysis revealed that these molecules induced zinc remobilization inside cells, resulting in bacterial zinc intoxication. More importantly, we also demonstrated that, upon treatment with these novel compounds, M. tuberculosis became even more sensitive to anti-tuberculosis drugs, in vitro and in vivo, in a mouse model of tuberculosis. Manipulation of heavy metal homeostasis holds thus great promise to be exploited to develop host-directed therapeutic interventions.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis 96%
- Essential Role of MHC II in the Antitubercular Efficacy of Pyrazinamide 95%
- Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays. 95%
Similar papers in this journal
- Targeting deubiquitinating enzymes (DUBs) and ubiquitin pathway modulators to enhance host defense against bacterial infections 96%
- A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases 95%
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication 94%
Similar papers in this journal
- Discovery of benzophenanthridine derivatives with potent activity against multidrug resistant Mycobacterium tuberculosis 94%
- Pentamidine inhibition of streptopain attenuates Streptococcus pyogenes virulence 94%
- Pharmacological inhibition of host pathways enhances macrophage killing of intracellular bacterial pathogens 94%
Similar papers in this journal
- PRMT5 epigenetically regulates the E3 ubiquitin ligase ITCH to influence lipid accumulation during mycobacterial infection 96%
- Fatty acid metabolism in neutrophils promotes lung damage and bacterial replication during tuberculosis. 95%
- Toxoplasma gondii requires its plant-like heme biosynthesis pathway for infection. 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.